Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Patients using Novo Nordisk's (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday. This information was shared at the European Congress on Obesity in Venice, Italy.
據報道，使用諾和諾德（紐約證券交易所代碼：NVO）（場外交易代碼：NONOF）肥胖症治療Wegovy的患者在四年內平均體重減輕了10％。這些信息是在意大利威尼斯舉行的歐洲肥胖問題大會上分享的。
What Happened: The data, derived from a large-scale study, most of which was published last year, could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug, countering the perception of it being merely a lifestyle drug, Reuters reported.
發生了什麼：路透社報道，這些數據來自一項大規模研究，其中大部分於去年公佈，有可能支持Novo對Wegovy的看法，因爲Wegovy試圖說服保險公司和政府支付該藥物的成本，這與人們認爲它只是一種生活方式藥物的看法背道而馳。
"This is the longest study we've conducted so far of semaglutide for weight loss," stated Martin Holst Lange, Novo's head of development.
Novo開發主管馬丁·霍爾斯特·蘭格說：“這是迄今爲止我們對索瑪魯肽進行的最長減肥研究。”
The trial involved 17,604 patients and tested Wegovy not for weight loss, but for its heart protective benefits for overweight and obese patients with preexisting heart disease but not diabetes. Participants were not required to track diet and exercise as it was not an obesity study.
該試驗涉及17,604名患者，對Wegovy的測試不是減肥，而是其對已有心臟病但未患有糖尿病的超重和肥胖患者的心臟保護作用。參與者無需追蹤飲食和運動情況，因爲這不是一項肥胖研究。
Why It Matters: Despite supply constraints and competition from Eli Lilly, the demand for Wegovy has been on the rise. The drug's sales more than doubled to 9.38 billion kroner ($1.35 billion) in the first quarter, although this figure fell short of analysts' estimates due to pricing pressure.
爲何重要：儘管存在供應限制和禮來公司的競爭，但對Wegovy的需求一直在上升。該藥在第一季度的銷售額翻了一番多，達到93.8億克朗（合13.5億美元），儘管由於定價壓力，這一數字未達到分析師的預期。
Tesla CEO Elon Musk recently endorsed Novo Nordisk's Ozempic, a GLP-1 agonist primarily prescribed to manage Type 2 diabetes, and sparked a conversation about childhood obesity and potential solutions.
特斯拉首席執行官埃隆·馬斯克最近認可了諾和諾德的Ozempic，這是一種 GLP-1 激動劑，主要用於治療 2 型糖尿病，並引發了關於兒童肥胖和潛在解決方案的討論。
On the other hand, Denmark's healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier GLP-1 drugs such as Novo Nordisk's Ozempic. This decision is expected to affect nearly half of all current GLP-1 drug users, who may switch to cheaper alternatives.
另一方面，丹麥醫療機構已決定爲2型糖尿病患者提供更便宜的藥物，這影響了Novo Nordisk的Ozempic等更昂貴的 GLP-1 藥物的處方。預計這一決定將影響當前所有 GLP-1 吸毒者的近一半，他們可能會轉向更便宜的替代品。
Price Action: On Monday, Novo Nordisk closed 3.09% higher on NYSE at $132.39, according to Benzinga Pro.
價格走勢：根據Benzinga Pro的數據，週一，諾和諾德在紐約證券交易所收盤上漲3.09％，至132.39美元。
Image Via Shutterstock
圖片來自 Shutterstock
譯文內容由第三人軟體翻譯。